文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas.

作者信息

Díaz Luis Antonio, Fuentes-López Eduardo, Ayares Gustavo, Idalsoaga Francisco, Arnold Jorge, Márquez-Lomas Andrea, Ramírez Carolina A, Medel María Paz, Viñuela Francisca, Lacalle Lucas, Roblero Juan Pablo, Ferreccio Catterina, Lazo Mariana, Brahmania Mayur, Singal Ashwani K, Dirchwolf Melisa, Méndez-Sánchez Nahum, Chavez-Tapia Norberto, Guerra Patricia, Restrepo Juan Carlos, Oliveira Claudia P, Lombardo Julissa, Sánchez Abel, Elizondo Martín, Tagle Martín, Padilla Martín, Sánchez Marco, Carrera Enrique, Girala Marcos, Chery Omega, Castellanos-Fernández Marlen, Barrera Francisco, Lazarus Jeffrey V, Kamath Patrick S, Bataller Ramon, Arrese Marco, Arab Juan Pablo

机构信息

Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, Chile.

Departamento de Ciencias de la Salud, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

出版信息

Lancet Gastroenterol Hepatol. 2022 Jun;7(6):552-559. doi: 10.1016/S2468-1253(22)00008-5. Epub 2022 Apr 14.


DOI:10.1016/S2468-1253(22)00008-5
PMID:35430032
Abstract

Non-alcoholic fatty liver disease (NAFLD) affects 20-25% of the general population and is associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD risk factors are modifiable and, therefore, potentially amenable to being reduced by public health policies. To date, there is no information about NAFLD-related public health policies in the Americas. In this study, we analysed data from 17 American countries and found that none have established national public health policies to decrease NAFLD-related burden. There is notable heterogeneity in the existence of public health policies to prevent NAFLD-related conditions. The most common public health policies were related to diabetes (15 [88%] countries), hypertension (14 [82%] countries), cardiovascular diseases (14 [82%] countries), obesity (nine [53%] countries), and dyslipidaemia (six [35%] of countries). Only seven (41%) countries had a registry of the burden of NAFLD, and efforts to raise awareness in the Americas were scarce. The implementation of public health policies are urgently needed in the Americas to decrease the burden of NAFLD.

摘要

相似文献

[1]
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas.

Lancet Gastroenterol Hepatol. 2022-6

[2]
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.

J Hepatol. 2020-1

[3]
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

J Hepatol. 2022-4

[4]
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

J Hepatol. 2018-6-8

[5]
NAFLD: Challenges and opportunities to address the public health problem in Latin America.

Ann Hepatol. 2021

[6]
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Lancet Gastroenterol Hepatol. 2020-5-12

[7]
European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?

JHEP Rep. 2021-1-21

[8]
Non-alcoholic fatty liver disease: A real threat in Pakistan.

J Pak Med Assoc. 2020-12

[9]
The prevalence of nonalcoholic fatty liver disease in the Americas.

Ann Hepatol. 2014

[10]
Non-alcoholic fatty liver disease: A growing public health problem in Turkey.

Turk J Gastroenterol. 2019-10

引用本文的文献

[1]
Association between a new indicator with non-alcoholic fatty liver and liver fibrosis in US adults: findings from NHANES 2017-2018.

Transl Gastroenterol Hepatol. 2025-7-8

[2]
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD).

Hepatol Commun. 2025-5-16

[3]
MetALD: New Perspectives on an Old Overlooked Disease.

Liver Int. 2025-5

[4]
Regional insights into the relationship between metabolic associated steatotic liver disease and chronic kidney disease: a socioeconomic perspective on disease correlation.

BMC Public Health. 2025-3-13

[5]
Association between the NHHR and hepatic steatosis and liver fibrosis: a population-based study.

Sci Rep. 2025-3-12

[6]
Reply to correspondence on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".

Clin Mol Hepatol. 2025-4

[7]
Impact of Helicobacter pylori Eradication on Clinical and Laboratory Parameters in Non-alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Curr Med Sci. 2025-2

[8]
Burden of NASH related liver cancer from 1990 to 2021 at the global, regional, and national levels.

Front Nutr. 2025-1-27

[9]
Associations between neighborhood built-environment characteristics and hepatic steatosis: The Multi-Ethnic Study of Atherosclerosis.

Health Place. 2025-1

[10]
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria.

Commun Med (Lond). 2024-10-29

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索